Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
March 07, 2017 16:02 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results...
Immune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017
March 01, 2017 17:24 ET
|
Immune Design Corp
– Preclinical Data Demonstrates Tumor Eradication with “Prime-Pull” Immunotherapy Approach Combining a ZVex® vector and G100 – – ZVex Causes Potent Activation of Dendritic Cells – SEATTLE...
Immune Design to Report Fourth Quarter and Year End 2016 Financial Results and Provide Corporate Update
March 01, 2017 16:01 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth...
Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
February 22, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S. Food...
Immune Design to Present at Upcoming Investor Conferences
February 10, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya,...
Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral Immunotherapy
December 05, 2016 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new data that highlight...
New Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual Meeting
November 11, 2016 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Ca., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new preclinical data...
Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 09, 2016 16:02 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results...
Immune Design to Report Third Quarter 2016 Financial Results & Present at Upcoming Investor Conference
November 02, 2016 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will...
Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer
October 04, 2016 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of...